Citations

Clear

6 citation(s) found for "Kumar, Aditi".

Elevated Dehydroepiandrosterone Sulfate Levels in 2 Patients With Prolactinomas: An Underrecognized Association
Arguinchona, Joseph , Yogi-Morren, Divya , Rad, Mona Vahidi, Doshi, Krupa , Kumar, Aditi, Vahidi Rad, Mona , Kumar, Aditi

Mayo Clinic

JCEM Case Reports | May 15, 2025 | Volume: 3 | Issue: 7 | Pages: No page available

10.1210/jcemcr/luaf111 | PMID 40384888 Get It

Abstract While adrenal androgen production is primarily regulated by ACTH, some data suggest a less common association between hyperprolactinemia and elevated dehydroepiandrosterone sulfate (DHEA-S). We describe 2 patients with this underrecognized connection. Patient 1, a 60-year-old male, was incidentally found to have bilateral adrenal masses on computed tomography during evaluation of gastrointestinal complaints. Further workup revealed elevated levels of DHEA-S and prolactin, with pituitary macroadenoma identified as the cause, given normalization of both prolactin and DHEA-S on cabergoline therapy. Patient 2, a 38-year-old male, presented with visual field defects, and subsequent pituitary magnetic resonance imaging confirmed a macroadenoma. He also had markedly elevated levels of DHEA-S and prolactin. Both patients were treated with cabergoline, leading to rapid normalization of both prolactin and DHEA-S levels. These cases demonstrate an association between hyperprolactinemia and elevated DHEA-S, supported by the normalization of levels with medical treatment of prolactinoma. Although hyperprolactinemia in the context of a prolactinoma is an uncommon cause of elevated DHEA-S, it should be considered once other etiologies have been excluded.
Insulin-Induced Lipohypertrophy
Rad, Mona Vahidi, Martínez-Gil, Mercedes , Vahidi Rad, Mona , Kumar, Aditi, Ahmed, Samir, Kumar, Aditi

Mayo Clinic

JCEM Case Reports | March 30, 2025 | Volume: 3 | Issue: 5 | Pages: No page available

10.1210/jcemcr/luaf059 | PMID 40162296 Get It

Pemetrexed‐carboplatin salvage therapy in advanced thyroid cancers
Lee, K. , Morris, John C. , Peskey, Candy S , Hilger, Crystal, Bible, Keith C. , Ryder, Mabel , Lee, Kenzie K , Kumar, Aditi, Peskey, Candy, Hilger, Crystal R, Ryder, Mabel , Morris, John C., Kumar, Aditi , Chintakuntlawar, Ashish V.

Mayo Clinic

Head & Neck | October 28, 2024 | Volume: 47 | Issue: 3 | Pages: 813-821

10.1002/hed.27940 | PMID 39462887 Get It

Abstract Background The overall survival of patients with advanced thyroid cancers that have progressed following targeted therapies is limited, indicating a strong need for salvage treatments. Methods We retrospectively analyzed patients with refractory advanced thyroid cancer treated with pemetrexed‐carboplatin (PC) at Mayo Clinic since 2019. Results Eleven patients, three with anaplastic thyroid cancer (ATC), seven with differentiated or poorly differentiated thyroid cancer (DTC), and one with oncocytic carcinoma of the thyroid, were treated with novel salvage PC. Patients with DTC ( n = 7) had durable responses with a median progression‐free survival of 29 months. One responder included a patient with ATC whose disease progressed following pembrolizumab/axitinib, lenvatinib, and dabrafenib/trametinib. On this fourth line treatment, the patient remains on therapy to date, over 12 months after initial response. Conclusions This case series reinforces prior published phase I clinical trial data and shows that pemetrexed can have potent efficacy in the treatment of the most advanced thyroid cancers.
5122 Severe Hypercalcemia as a Manifestation of Immune Reconstitution Inflammatory Syndrome in a Patient with AIDS and Disseminated MAC Infection
Rad, Mona Vahidi, Ahmed, Samir, Kumar, Aditi

Mayo Clinic

Journal of the Endocrine Society | October 5, 2024 | Volume: 8 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvae163.497 Get It

Abstract Disclosure: M. Vahidi Rad: None. S. Ahmed: None. A. Kumar: None. Introduction: Granulomatous disease can cause hypercalcemia due to increased production of 1,25 dihydroxyvitamin-D. Mycobacterium avium complex (MAC) infection is an AIDS (acquired immunodeficiency syndrome)-defining illness and a granulomatous disease that can lead to hypercalcemia. We report a case of severe hypercalcemia from Immune Reconstitution Inflammatory Syndrome (IRIS) in a patient with AIDS and disseminated MAC which developed several months after initiation of appropriate antibiotic and antiviral therapy. Clinical Case: A 30-year-old female with HIV on anti-retroviral therapy and disseminated MAC infection on antibiotics developed PTH independent mild hypercalcemia in the 10.9-11.5 mg/dL range about 4 months after initiation of antiviral and antibiotic therapy. 1,25 dihydroxyvitamin D level was normal at 50 pg/mL (reference range 18-78 pg/mL). The hypercalcemia worsened and about 8 months after initiation of antimicrobial therapy, she had a hospitalization for severe hypercalcemia with corrected calcium of 15.2 mg/dL and acute kidney injury. PTH was suppressed at 6.9 pg/mL and repeat 1,25 dihydroxyvitamin D level was elevated at 129 pg/mL (reference range 18-78 pg/mL). Other testing for PTH independent hypercalcemia including PTH- Related Peptide, serum protein electrophoresis (SPEP) and TSH were normal. She was diagnosed with hypercalcemia from increased calcitriol production in the setting of IRIS secondary to disseminated MAC. Hypercalcemia secondary to increased production of calcitriol in patients with MAC and HIV infection might happen or worsen months after starting the antimicrobial treatments and has been reported as a potential manifestation of immune reconstitution. MAC-associated IRIS has been reported to be associated with a T-helper cell response with increased number of interferon-gamma-producing T-cells and Th1-cytokines that can potentially cause a granulomatous reaction. These granulomas will have increased macrophage 1-alpha-hydroxylase activity that can further result in more production of 1,25 dihydroxyvitamin D3 and cause more hypercalcemia. Prednisone was started with resultant improvement in hypercalcemia. Conclusion: Severe hypercalcemia due to worsening of subclinical granulomatous infections such as MAC can be a manifestation of IRIS in patients with HIV infection or AIDS who are on antiretroviral treatments. This responds to glucocorticoids. Presentation: 6/2/2024
An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer
Bible, Keith C. , Menefee, Michael E., Millward, Michael , Maples, William J., Karlin, Nina J. , Kane, Madeleine, Molina, Julian R. , Donehower, Ross C. , Lim, Wan‐Teck , Flynn, Patrick J. , Richardson, Ronald L., Traynor, Anne M. , Rubin, Joseph, LoRusso, Patricia , Smallridge, Robert C., Burton, Jill K., Voss, Jessie S., Rumilla, Kandalaria M., Kipp, Benjamin R. , Harris, Pamela Jo , Erlichman, Charles , Kumar, Aditi, Lin, Chia‐Chi , Goh, Boon Cher , Adkins, Douglas R. , Suman, Vera J. , Kumar, Aditi , Chintakuntlawar, Ashish V.

Mayo Clinic

Thyroid® | June 15, 2020 | Volume: 30 | Issue: 9 | Pages: 1254-1262

10.1089/thy.2019.0269 | PMID 32538690 Get It

Introduction: Multikinase inhibitors have clinical activity in radioactive iodine refractory (RAIR) differentiated thyroid cancers (DTCs) but are not curative; optimal management and salvage therapies remain unclear. This study assessed clinical effects of pazopanib therapy in RAIR-DTC patients with progressive disease, examining in parallel biomarker that might forecast/precede therapeutic response. Methods: Assessment of responses and toxicities and of any association between thyroglobulin (Tg) changes cycle 1 and RECIST (response evaluation criteria in solid tumors) response to pazopanib therapy were prospectively undertaken in Tg antibody negative RAIR-DTC patients. RECIST progressive metastatic disease <6 months preceding enrollment was required. With a sample size of 68 (assuming 23 attaining partial response [PR]), there would be 90% chance of detecting a difference of >30% when the proportion of patients attaining PR whose Tg values decrease by >50% is >50% cycle 1 (one-sided α = 0.10, two sample test of proportions). Mean corpuscular volume (MCV) change or mutational status or pretreatment were also explored as early correlates of eventual RECIST response. Results: From 2009 to 2011, 60 individuals were treated and evaluated; (one additional patient withdrew; another was found ineligible before therapy initiation); 91.7% had previous systemic therapy beyond RAI. Adverse events included one death (thromboembolic) deemed possibly pazopanib associated. Twenty-two confirmed RECIST PRs resulted (36.7%, confidence interval; CI [24.6–50.1]); mean administered 4-week cycles was 10. Among 44 fully accessible patients, the Tg nadir was greater among the 20 attaining PR (median: −86.8%; interquartile range [IQR]: −90.7% to −70.9%) compared with the 28 who did not (median: −69.0%; IQR: −78.1% to −27.7%, Wilcoxon rank-sum test: p = 0.002). However, the difference in the proportion of PRs among those whose Tg fell ≥50% after cycle 1 versus those that did not were not significantly correlated (−23.5% [CI: −55.3 to 8.3]; Fisher's exact test p -value = 0.27). RECIST response was also not correlated with/predicted by early MCV change, receipt of prior therapy, or tumor mutational status. Conclusions: This trial prospectively confirmed pazopanib to have clinical activity and manageable toxicities in patients with progressive RAIR-DTC. Response to pazopanib, however, was not robustly forecast by early associated changes in Tg or MCV, by prior therapy, or by tumor mutational status. ClinicalTrials.gov NCT00625846.
Effects of pazopanib therapy on mean corpuscular volume in patients enrolled in MC1112: Analysis of correlation with time to disease progression in solid tumors.
Burton, Jill K., Qin, Rui , Erlichman, Charles , Harris, Pamela Jo , Bible, Keith C. , Kumar, Aditi , Suman, Vera J. , Haluska, Paul

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e13596-e13596

10.1200/jco.2015.33.15_suppl.e13596 Get It